The aim of this study was to investigate the effects of cucurbitacin R on an experimental model of adjuvant-induced arthritis in rats. The treatment of arthritic rats with cucurbitacin R (1 mg/kg p.o. daily) modified the evolution of the clinical symptoms, whereas the histopathology of paws demonstrated a reduction in the signs of arthritis. Compared with the control group, radiography of the tibiotarsal joints of cucurbitacin Rtreated rats showed a decrease in joint damage and soft tissue swelling of the footpad. The in vivo study of the expression of proinflammatory enzymes (nitric-oxide synthase-2 and cyclooxygenase-2) with the aid of the Western blot technique, and that of tumor necrosis factor-␣ (TNF-␣) and prostaglandin E 2 by means of enzyme-linked immunosorbent assays demonstrated a clear decrease in both the enzymes and the mediators in paw homogenates. The analysis for prostaglandin E 2 , nitric oxide, and TNF-␣ production in RAW 264.7 macrophages, as well as that for TNF-␣ in human lymphocytes, indicated a reduction of all mediators. The expression of cyclooxygenase-2 was not modified in RAW 264.7 macrophages, whereas the expression of nitric-oxide synthase-2 was clearly diminished. Moreover, cucurbitacin R was found to inhibit signal transducer and activator of transcription 3 activation in the lymphocytes of both healthy and arthritic men. These experimental data on the chronic model, together with previously reported activity on acute and subchronic experimental models, justify the antiinflammatory activity of cucurbitacin R and provide further evidence for the therapeutic potential of a group of natural products as anti-inflammatory agents.Arthritis is a chronic disease that affects several parts of the joints such as the cartilage, synovium, tendons, and muscles. Rheumatoid arthritis is a specific type of this disease characterized by chronic inflammation of the joints, with severe cartilage and bone damage. The precise causes are unknown, but genetics, infectious agents, environment, and hormonal effects have all been implicated. Treatments are focused on the reduction of pain, inflammation, and joint damage. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, glucocorticoids, and specific inhibitors of the mediator response such as the tumor necrosis factor-␣ (TNF-␣) antibody infliximab. Adjuvant arthritis is an experimental model unique to rats that is widely used for studying the physiology, biochemistry, and pharmacology of inflammation and also as a model of cell-mediated autoimmnune disease, human arthritis, and chronic pain. Different parameters can be evaluated, such as weight evolution, paw swelling, histology, immunohistochemistry, and radiographic evaluation (Taurog et al., 1988). The origin and development are complex, with the implication of different inflammatory cells and cytokines. Thus, when the inflammatory cells migrate into the joint space between bones, there is inflammation of the membranes and damage...